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Background: Predicting vaccine efficacy against emerging pathogen strains is a signifi-
cant problem in human and animal vaccine design. T- cell epitope cross- conservation 
may play an important role in cross- strain vaccine efficacy. While influenza A virus 
(IAV) hemagglutination inhibition (HI) antibody titers are widely used to predict pro-
tective efficacy of 1 IAV vaccine against new strains, no similar correlate of protection 
has been identified for T- cell epitopes.
Objective: We developed a computational method (EpiCC) that facilitates pairwise 
comparison of protein sequences based on an immunological property—T- cell epitope 
content—rather than sequence identity, and evaluated its ability to classify swine IAV 
strain relatedness to estimate cross- protective potential of a vaccine strain for circulat-
ing viruses.
Methods: T- cell epitope relatedness scores were assessed for 23 IAV HA sequences 
representing the major H1 swine IAV phylo- clusters circulating in North American 
swine and HA sequences in a commercial inactivated vaccine (FluSure XP®). Scores 
were compared to experimental data from previous efficacy studies.
Results: Higher EpiCC scores were associated with greater protection by the vaccine 
against strains for 23 field IAV strain vaccine comparisons. A threshold for EpiCC re-
latedness associated with full or partial protection in the absence of cross-reactive HI 
antibodies was identified. EpiCC scores for field strains for which FluSure protective 
efficacy is not yet available were also calculated.
Conclusion: EpiCC thresholds can be evaluated for predictive accuracy of protection 
in future efficacy studies. EpiCC may also complement HI cross- reactivity and phylog-
eny for selection of influenza strains in vaccine development.
K E Y W O R D S
computational immunology, hemagglutinin, influenza A viruses, swine influenza H1 viruses, swine 
leukocyte antigen, T-cell epitope content comparison, T-cell epitope prediction, vaccine efficacy
1  | INTRODUCTION
Influenza A viruses (IAVs) cause a highly contagious respiratory 
disease in swine, a problem that has a significant impact on food 
production.1 Predicting whether existing vaccines will protect 
against newly emergent strains circulating in pig herds is a signif-
icant problem for pork producers. Hemagglutinin (HA) and neur-
aminidase (NA) are the 2 major surface glycoproteins that define 
532  |     GUTIÉRREZ ET al.
IAV subtypes and play a key role in antigenicity, pathogenesis, host 
range, and protection in the context of vaccination. The segmented 
IAV genome allows for antigenic shift by reassortment of RNA seg-
ments from different viral strains infecting the same cell, generating 
novel viruses.2 Antigenic drift due to accumulation of mutations in 
HA and NA contributes to the remarkable diversity of IAVs2 and im-
pedes the development of broadly effective IAV vaccines for both 
pigs and humans.
Currently, H1N1, H1N2, and H3N2 are the predominant IAV sub-
types cocirculating in the North American swine population. These 
subtypes are further subdivided based on the genetic and antigenic 
properties of HA. For H1 viruses, 7 distinct genetic phylo- clusters (α, 
β, γ, γ- 2, δ1, δ2, and pandemic (pdm09)) have been identified.3 The HA 
gene of α, β γ, and pdm09 cluster viruses is most similar to classical 
swine H1N1 (cH1N1).3 HA from human- origin δ viruses can be dif-
ferentiated in 2 subclusters, δ1 and δ2.4 Due to antigenic variability of 
HA, serological cross- reactivity between H1 clusters similar to cH1N1 
is variable, and there is very limited serologic cross- reactivity be-
tween these viruses and the even more divergent δ cluster viruses.3,5 
Whether for swine IAV or for human IAV, methods for predicting 
whether a vaccine will protect against emerging IAVs, when serological 
cross-reactivity is absent, are needed.
Most of the North American commercial vaccines against swine 
IAV contain inactivated viruses. The predominant antibody responses 
induced by these vaccines are to the HA protein.1,6 Therefore, 
hemagglutination- inhibiting (HI) antibody titers, in addition to se-
quence analysis of HAs, are used to evaluate the potential for 1 vaccine 
to protect against variant strains.6 However, full or partial protection in 
pigs can still be observed (based on reduction in lung lesions and viral 
titers) following vaccination with inactivated commercial vaccines, de-
spite the absence of cross-reactive antibodies post-vaccination.1,6-12
Protection in the absence of neutralizing antibodies is attributed to 
T cell–mediated responses to cross- conserved T- cell epitopes.13,14 For 
example, in humans, immunity to cross- conserved epitopes during the 
2009 H1N1 IAV pandemic may have contributed to attenuation of mor-
bidity in some age groups.13,15 In mice, a DNA vaccine based on 8 HA T- 
cell epitopes and 1 NA epitope that were conserved between seasonal 
and pdm09 strains lowered lung viral loads in HLA- DR3 transgenic mice 
challenged with pdm09 in the absence of antibody responses.16 Other 
murine studies have shown that cross- protection induced by conserved 
antigens does not provide complete protection against infection, but 
reduces mortality, morbidity, virus replication, and viral shedding.17,18 
Protection in these instances is believed to be due to the recognition 
of conserved, linear T- cell epitopes presented by class I or class II major 
histocompatibility complex (MHC) molecules to cytotoxic T lympho-
cytes (CTL, CD8) and T- helper (Th, CD4) lymphocytes.19
As T- cell epitopes that are similar in vaccine and challenge strains 
may be responsible for protection in the absence of cross- reactive an-
tibodies, we developed a method for T- cell epitope content compar-
ison (EpiCC) that assesses the relatedness of class I and II epitopes 
across antigens and predicts potential vaccine efficacy based on a 
relatedness threshold. Using this method, we evaluated whether T- 
cell epitope relatedness could explain protection of pigs that were 
vaccinated with a commercial inactivated vaccine and challenged with 
heterologous H1N1 IAV when cross- reactive antibodies were absent.
EpiCC differs from strict sequence- based methods for compar-
ing vaccine and outbreak strains. It uses PigMatrix, an algorithm that 
predicts class I and II T- cell epitopes specific to swine MHC (Swine 
Leukocyte Antigen, SLA) alleles20 while also analyzing the TCR- facing 
residues of T- cell epitopes, to predict and assess epitope similarities 
between input pathogen protein sequences. PigMatrix and associated 
tools that comprise the iVAX vaccine design toolkit were previously val-
idated in retrospective and prospective studies of SLA- restricted influ-
enza epitopes.21,22 Here, we used EpiCC to determine the T- cell epitope 
relatedness of HA proteins from 23 swine IAV strains representing the 
major H1 phylo- clusters circulating in the North American swine popula-
tion. As the internal genes in North American swine influenza have been 
highly conserved between strains since 1998 (due to the emergence of 
the triple- reassortant internal gene [TRIG] cassette), we assumed mini-
mal T- cell epitope differences in those antigens and focused our analysis 
instead on the critical and most variable swine IAV antigen, HA.3,23,24 
Comparing the results of previously performed vaccine efficacy studies 
with IAV EpiCC scores, we were able to identify a level of T- cell epitope 
relatedness for a γ- cluster H1N1 vaccine virus that could be associated 
with full or partial vaccine efficacy for this set of 23 IAV strains.
2  | METHODS
2.1 | Sequences
Hemagglutinin sequences from 23 H1 IAV strains were included in the 
analysis (Table 1). Sequences were either obtained from GenBank or 
provided by Zoetis. Twenty of these HA sequences were from swine 
H1 viruses representing the α, β, γ, γ- 2, δ1, δ2, and pdm09 phylo- 
clusters, and 3 of the sequences were from strains (belonging to the 
γ, δ1, and δ2 H1 phylo- clusters) included in FluSure XP (FS; Zoetis 
Inc., Florham Park, NJ, USA). Phylogenetic analysis was performed the 
using MEGA7.25 All 23 HA amino acid sequences were aligned with 
MUSCLE, and an evolutionary tree was defined using the maximum- 
likelihood method with 500 bootstrap replicates.
2.2 | MHC binding prediction
The HA amino acid sequences of the 23 IAV strains were screened using 
PigMatrix.20 PigMatrix parses sequences into 9- mers and assesses the 
binding potential of each 9- mer i to SLA class I and II alleles. For each 
individual allele a in a set of MHC alleles A, PigMatrix raw scores r are 
normalized to Z- scores using the average μ and the standard deviation 
σ of scores calculated for 100 000 random 9- mers as previously de-
scribed for EpiMatrix (a human T- cell epitope prediction tool).26
In this normalized set of scores for each SLA allele, 9- mers with Z- 
scores above 1.64 comprise the top 5% of sequences with significant 
SLA binding potential. Increasing Z- scores correlate with higher MHC 
Z(i)a=
(r−μ)
σ
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binding probability. The same thresholds for defining low, medium, 
and high probability MHC binders are applied as have been previously 
used in EpiMatrix studies.26
The distribution of SLA alleles among pig herds in the United States 
is unknown. Binding was therefore predicted to a set of SLA class I 
and II alleles that were frequently expressed in a cohort tested in a 
previous study (SLA- I: SLA- 1*0801, 1*1201, 1*1301, 2*0501, 2*1201, 
3*0501, 3*0601, and 3*0701; SLA- II: SLA- DRB1*0201, 0402, 0602, 
0701, and 1001).22
As data are lacking on breadth of coverage for SLA (the ability 
for selected SLA alleles to cover an outbred population of pigs), the 
set of sequences was also evaluated using HLA alleles for which the 
breadth of coverage is known.27,28 We quantified the HLA- restricted 
T- cell epitopes that could be identified in these IAV sequences and 
compared to the epitopes uncovered using the set of SLA selected 
for this study. The breadth of coverage comparison was performed 
using the following HLA class I and class II supertype alleles: HLA- I: 
A*0101, A*0201, A*0301, A*2402, B*0702, and B*4403; and HLA- II: 
DRB1*0101, 0301, 0401, 0701, 1101, 1301, and 1501.29
2.3 | T- cell epitope content comparison
EpiCC assesses the relatedness of T- cell epitopes contained in a 
protein sequence of a strain s and those contained in a protein se-
quence of a vaccine strain v based on a comparison of the epitope 
sequences and their PigMatrix SLA binding score, using a set of 
MHC alleles A. For any comparison, T- cell epitopes can be either 
shared (conserved) between sequences, or unique to the strain, or 
unique to the vaccine. Thus, the EpiCC score for the comparison 
between s and v (EpiCC score or T- cell epitope- based relatedness) 
is based on the PigMatrix scores of shared and unique epitopes (Fig. 
S1).
Intuitively, the epitope content of a protein depends on its epitope 
density. So, if a “high–epitope density” protein is compared to a highly 
similar protein and many of their epitopes are conserved or shared 
between the 2 strains, the scores of shared epitopes will be high; con-
sequently, the score of the comparison of their epitope content (EpiCC 
score) will also be high. As PigMatrix binding probabilities of s and v are 
considered for the calculation, the EpiCC score will be even higher if 
TABLE  1 Hemagglutinin sequence information for swine H1 influenza A viruses
Virus namea Virus H1 cluster Labelb
GenBank accession  
or sourcec
A/swine/Iowa/15/1930 (H1N1) Classical IA30 cH1 EU139823
A/swine/Illinois/02450/2008 (H1N1) α IL08 H1α CY099052
A/swine/South Dakota/A01823598/2015 (H1N2) α SD15 H1α KT356682
A/swine/St- Hyacinthe/106/1991 (H1N1) α SH91 H1α U11857
A/swine/Iowa/40766/1992 (H1N1) α IA92 H1α KP788773
A/swine/Minnesota/00040/2002 (H1N1) β MN02 H1β Zoetis
A/swine/Iowa/00239/2004 (H1N1) β IA04 H1β KM198690
A/swine/Iowa/110600/2000 (H1N1) γ IA00 H1γ FS Zoetis
A/swine/Minnesota/PAH618/2011 (H1N1) γ MN11 H1γ Zoetis
A/swine/Ohio/02973/2010 (H1N1) γ OH10 H1γ Zoetis
A/swine/Iowa/A01940123/2015 (H1N1) γ IA15 H1γ KT699044
A/swine/Minnesota/A01940015/2015 (H1N1) γ MN15 H1γ KT595733
A/swine/Iowa/A01410129/2012 (H1N1) γ2 IA12 H1γ- 2 KJ397936
A/California/04/2009 (H1N1) H1N1pdm09 CA09 H1pdm GQ117044
A/swine/Oklahoma/0726H/2008 (H1N2) δ1 OK08 H1δ1 FS Zoetis
A/swine/Ontario/55383/04 (H1N2) δ1 ON04 H1δ1 DQ280212
A/swine/Illinois/PAH710/2011 (H1N2) δ1 IL11 H1δ1 Zoetis
A/swine/South Dakota/A01823304/2015 (H1N2) δ1 SD15 H1δ1 KT277819
A/swine/Oklahoma/A01566774/2014 (H1N2) δ1 OK14 H1δ1 KP270784
A/swine/Minnesota/A01823864/2015 (H1N2) δ1 MN15a H1δ1 KT699050
A/swine/Iowa/A01823426/2015 (H1N2) δ1 IA15 H1δ1 KT356694
A/swine/Minnesota/A01940042/2015 (H1N2) δ1 MN15b H1δ1 KT733589
A/swine/North Carolina/031/2005 (H1N1) δ2 NC05 H1δ2 FS Zoetis
A/swine/NC/00573/2005 (H1N1) δ2 NC05 H1δ2 FJ638306
aFS viruses are shown in bold font.
bFS viruses have “FS” at the end of their labels.
cSequences marked “Zoetis” were provided by Zoetis and are considered proprietary.
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the shared 9- mer epitopes have high predicted binding probabilities to 
the alleles in the set A.
We hypothesized that if epitopes in a vaccine closely match the 
epitopes in the challenge strain, and vaccine- and strain- unique epi-
topes are rare, the memory T cells induced by the vaccine are likely 
to recognize the epitopes in the proteins of the challenge strain. The 
model assumes (i) that there is no prior T- cell memory to the epitopes 
(a naïve immune system); (ii) that vaccination does not induce memory 
T cells to epitopes that are unique to the challenge strain; and (iii) that 
the efficacy of the vaccine might be adversely affected by the pres-
ence of many vaccine- unique epitopes.30 Consequently, in our calcu-
lation, the EpiCC score of 2 sequences is improved by the presence of 
shared epitopes but decreases with increasing numbers of strain- and 
vaccine- unique epitopes. The impact of “unique” epitopes could be ad-
justed in future comparisons.
The first step in calculating the EpiCC score is to obtain T- cell 
epitope predictions for s and v using PigMatrix. Each 9- mer i∈s is 
compared to a corresponding 9- mer j∈v. The pairs of 9- mers i,j are de-
termined from a local alignment of s and v sequences using the Smith- 
Waterman algorithm from EMBOSS.31 For i,j where one of the 9- mers 
has a gap in position 1, that 9- mer is considered “nonexistent,” that is, 
excluded from comparison.
For each of the pairs i,j and for each allele a∈A, the score of a 
shared T- cell epitope S(i,j)a is computed only for epitopes that are 
cross- conserved (ie, i,j with identical residues that face the TCR and 
predicted to bind to allele a). We reasoned that epitopes with iden-
tical TCR- facing residues (TCRf), which are also predicted to bind 
to the same MHC allele, are more likely to induce cross- reactive 
memory T cells. This is a simple assumption because a TCR can 
recognize peptides with different TCRf,32 but it is a conservative 
initial approach to define potential cross- reactive epitopes.33 For 
class I T- cell epitope comparison, we assumed that i and j are cross- 
conserved, and potentially cross- reactive, if they have identical res-
idues in positions 4, 5, 6, 7, and 8 and are predicted to bind to a, 
regardless of differences on their MHC- facing amino acids. For class 
II, amino acids in positions 2, 3, 5, 7, and 8 were considered TCRf. 
Positions were selected based on published analysis of peptide- 
MHC- TCR crystal structures.34 S(i,j)a is calculated using predicted 
binding probabilities as follows:
where p is the cumulative probability in the normal distribution for the 
Z- score. As the binding of i and j to allele a is independent, S(i,j)a, the 
probability of them both occurring, is the product of the probabilities 
of each occurring (ie, joint probability).
The score of a unique epitope U(i,j)a is determined for non- cross- 
conserved epitopes based on binding probabilities according to these 
criteria:
1. Score of a strain-unique epitope: if Z(i)a>1.64→U(i,j)a=p(i)a
2. Score of a vaccine-unique epitope: if Z(j)a>1.64→U(i,j)a=p(j)a
Note that for any given i,j, predicted epitopes cannot be both 
shared and unique for allele a, but they can be both strain- unique and 
vaccine- unique if i and j are predicted to bind allele a, and their TCRf 
are distinct. For i,j where both 9- mers are not predicted to bind allele 
a, S(i,j)a and U(i,j)a are undetermined.
As the alleles in A are distinct, they are treated independently; 
hence, the score of shared epitopes for i,j over the full set of alleles can 
be calculated as a joint probability (ie, product of the shared binding 
probabilities for individual alleles). However, given that the score of a 
shared epitope is calculated only for i,j where both 9- mers are pre-
dicted to be binders, the joint probability over multiple alleles under-
weights shared promiscuous epitopes. For this reason, we computed 
the sum of the probabilities instead.
For the calculation of the EpiCC score, we assume that binding 
of each 9- mer epitope is mutually exclusive and uniform. Thus, E is 
the sum of shared and unique epitope scores of each i,j normalized by 
the total number of compared pairs p to account for variable epitope 
densities, and by the number of MHC alleles in A allowing for compari-
son of values of E determined using different numbers of MHC alleles. 
Formally, the EpiCC score for sequences from a vaccine and strain is 
computed as:
The sum of class I and II E(s,v)A is the total epitope- based related-
ness score for s and v. Note that U(i,j)a functions as a penalty; there-
fore, if U(i,j)a>S(i,j)a, E(s,v)A is negative.
Comparison of the predicted epitope content of any sequence 
to itself defines the sequence’s baseline EpiCC score (E(s,s)A; Fig. 
S1) and it represents the predicted epitope density of the sequence 
and the binding probabilities of its epitopes. It follows that the 
maximum value of any comparison between a vaccine strain and a 
challenge strain E(s,v)A can only be less than or equal to E(v,v)A or 
E(s,s)A. For vaccines with low T- cell epitope content, the baseline 
EpiCC score E(v,v)A will be low, and the comparison score E(s,v)A 
will be also low, even if s and v epitopes are highly similar. Thus, 
low E(s,v)A can be due either to low T- cell epitope content of 1 
or both sequences and/or to low epitope relatedness between the 
strains.
2.4 | HA baseline EpiCC score comparison
We calculated the baseline EpiCC score of the HA sequence of each 
viral strain (E(s,s)A). So as to evaluate whether the selection of specific 
sets of MHC alleles had an effect on the baseline EpiCC scores, E(s,s)A 
was calculated using the epitope content predicted with 4 different 
sets of MHC alleles. Specifically, we compared EpiCC scores calcu-
lated with swine allele sets SLA- I and SLA- II to EpiCC scores calcu-
lated with human allele sets HLA- I and HLA- II.
2.5 | Comparison of HA T- cell epitope content 
between field and vaccine viruses
To test whether we could determine an EpiCC score that defined full 
or partial protection, we compared the epitope content (predicted 
S(i,j)a=p(i)a ⋅p(j)a
E(s,v)A=
1
|p| ⋅ |A|
∑
iϵs;jϵv
∑
aϵA
S(i,j)a−U(i,j)a
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using SLA alleles) of each HA to that of FS vaccine viruses (E(s,v)A). 
Shared and unique class I, class II and total EpiCC scores were 
determined. We also explored the relationships between protein 
identity and EpiCC scores using regressions. To represent the lower 
end of the sequence identity spectrum, we included HA sequences 
from A/Missouri/2124514/2006 (H2N3), A/Guangxi/592/2011 
(H5N1), A/swine/Mexico/GtoDMZC02/2014 (H5N2), A/swine/ 
North Carolina/A01442548/2012 (H3N2), and A/swine/Missouri/ 
A01727926/2015 (H4N6) viruses (GenBank accessions EU258939, 
KM027999, KU141372, KC445235, and KU641621, respectively); 
their HA amino acid sequences had identities between 41.1% and 
64.61% when compared to the sequence of HA from FS viruses. 
A random sequence that had the same number of amino acids as 
the average HA sequence in this data set and the average (natural) 
amino acid frequencies of proteins in the Swiss- Prot database was 
also included in the comparison.
2.6 | Relationship between EpiCC scores and 
vaccine efficacy
The goal of this analysis was to determine whether a certain level of 
T- cell epitope relatedness of HA could be associated with protection 
afforded by vaccination in the absence of cross- reactive antibodies 
in pre- challenge sera, assuming minimal variation in T- cell epitope 
content among internal proteins. We therefore evaluated whether 
the experimental outcomes of six previously performed FS H1N1γ 
vaccination and H1N1 challenge studies could be predicted using a 
defined EpiCC score threshold. For this analysis, FS was considered 
to be protective if it significantly reduced the percentage of lung 
lesions and viral titers in nasal swabs (ie, nasal shedding) and/or in 
the lung or lung lavage. The EpiCC score threshold associated with 
protection was defined as the lowest EpiCC score for the compari-
son between the FS H1γ vaccine virus and challenge viruses, where 
studies demonstrated that the inactivated vaccine was protective. 
EpiCC scoring was performed independently and prior to obtaining 
information about the outcomes of the vaccination and challenge 
studies.
2.7 | Statistical analysis
Wilcoxon matched- pairs signed rank test was used to compare base-
line EpiCC score of HA sequences defined using different sets of MHC 
alleles (eg, E(s,s)SLA-I vs E(s,s)SLA-II; E(s,s)SLA-I vs E(s,s)HLA-I). The same test 
was applied to evaluate differences between SLA class I and II EpiCC 
scores for each vaccine virus. Correlation between class I and II base-
line EpiCC scores was determined using the nonparametric Spearman 
correlation coefficient (ρ). Correlation of class I and II EpiCC scores 
was evaluated using the same test. We used Pearson correlation (r) 
to evaluate the relationship between sequence identity and EpiCC 
scores. P- values (p) less than .05 were deemed significant. Analyses 
were performed using R 3.3.1 (Foundation for Statistical Computing, 
Vienna, Austria).
3  | RESULTS
3.1 | Baseline EpiCC scores for E(s,s)A
HA amino acid sequences from different swine IAV phylo- clusters 
(Figure 1) representing a range of sequence identities (from high to 
low) were analyzed. Although inactivated whole- virus vaccines for 
influenza contain many antigens, the critical protective antigen (and 
the most variable) is considered to be HA. Thus, for this analysis, we 
calculated EpiCC for HA and did not include internal proteins in the 
calculations. Across the 23 H1 viruses, baseline HA SLA class I EpiCC 
scores, E(s,s)SLA-I, were significantly lower (P < .001) and less variable 
(0.049 (0.001); mean (standard deviation)) than class II EpiCC scores 
(E(s,s)SLA-II, 0.068 (0.004)) (Fig. S2A), and they were not significantly cor-
related (ρ = 0.18, P = .19). HA proteins from recently reported H1δ1 
cluster viruses had the highest class II and total baseline EpiCC scores.
3.2 | SLA vs HLA
To evaluate the effect of allele specificity and the breadth of cover-
age of the set of SLA alleles, we compared the baseline EpiCC scores 
predicted using SLA alleles to that predicted using human supertype 
HLA alleles. The baseline class I HLA allele- defined EpiCC scores 
(E(s,s)HLA-I, 0.063 (0.002)) were significantly higher (P < .001) than 
those predicted using SLA alleles (E(s,s)SLA-I (0.049 (0.001); Fig. S2B). 
Baseline HLA class II EpiCC scores (E(s,s)HLA-II (0.065 (0.004)) were 
significantly lower (P < .05) than those predicted using SLA class II al-
leles (E(s,s)SLA-II (0.068 (0.004); Fig. S2C). The relevance of this finding 
is unknown. The lower baseline scores observed for SLA class I alleles 
F I G U R E  1 Phylogenetic tree for the Hemagglutinin (HA) amino 
acid sequences of influenza A field and FluSure vaccine (FS) viruses 
representing H1 phylo- cluster in the North American swine. 
Bootstrap test results are shown next to the branches
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as compared to HLA class I alleles may indicate that the set of SLA- I 
alleles selected for this study was not as broad in terms of population 
coverage of swine, and might not capture all the T- cell epitope differ-
ences between strains. Alternatively, the HA sequences of the ana-
lyzed IAV may contain fewer epitopes that bind to SLA class I alleles. 
This could also be true for human class I epitope content in IAV, as 
the IAV strains had lower (P = .04) HLA class I baseline EpiCC scores 
compared to those of HLA class II using supertype HLA alleles (Fig. 
S2D). The number of reported class I epitopes defined for IAV in gen-
eral (based on published data in the Immune Epitope Database35) also 
seems to be lower than the number of epitopes defined in IAV that are 
restricted by class II; thus, the differences described here are consist-
ent with previous observations and may be relevant to pathogenesis.
3.3 | Comparison of T- cell epitope content between 
field and vaccine viruses
We then compared the SLA class I and II epitope content predicted for 
HA of each field virus to that of the vaccine viruses, E(s,v). Intuitively, 
HA proteins from similar strains will have similar epitope content. 
Thus, HA sequences from viruses within the same H1 cluster or in a 
cluster of the same HA lineage (cH1N1 or human seasonal) had higher 
scores for class I and II shared epitopes and lower scores for unique 
epitopes than viruses in clusters from a different HA lineage (Figure 2). 
It is noteworthy that there were shared epitopes in all comparisons, 
even when comparing viruses from different HA lineages.
Scores of shared, strain–unique, and vaccine- unique SLA class II 
epitopes were significantly higher than those for SLA class I (P < .001 
for the 3 vaccine viruses), except for scores of H1γ FS vaccine- unique 
epitopes (P = .05). Likewise, using HLA supertype alleles, scores of 
class II shared epitopes were also significantly higher than those for 
class I (P < .01; Fig. S3). Class II scores of unique epitopes were also 
higher for OK08 H1δ1 FS (vaccine- unique) and NC05 H1δ2 FS (strain- 
unique). As mentioned above, although the population coverage of the 
set of SLA class I may be limited, the fact that the same lack of class 
I epitopes was observed for HLA supertype alleles suggests that the 
analyzed HA sequences had lower class I epitope content than class 
II content.
We used radar plots to facilitate the comparison of EpiCC scores 
between the vaccine and challenge strains. The EpiCC scores are dis-
played on these plots as a distance along a radiating line that also pro-
vides information on the relative sequence identity of the individual 
F I G U R E  2 Comparison of scores of shared and unique epitopes across strains. Scores of shared, vaccine- unique, and strain- unique swine 
leukocyte antigen class I and II epitopes were determined for the comparison of hemagglutinin (HA) sequences from vaccine viruses and field 
(challenge) strains. Note that y- axes show different scales. Solid connecting lines are included only for visualization purposes. P- values of 
comparisons were calculated using 1- tailed Wilcoxon matched- pairs signed rank test (**P < .001). HA vaccine sequences had higher scores for 
shared epitopes with strains belonging to the same H1 cluster or the same HA lineage. In general, scores of class II shared and unique epitopes 
were significantly higher than those of class I. Viruses are sorted by nucleotide identity relative to H1γ FS. Strain numbers on the x- axis are 
described in detail in the legend below
** 
** 
** 
**
**
** 
**
** 
1:IA00 H1  FS 4:OH10 H1 7:IA15 H1 10:SH91 H1 13:SD15 H1 16:NC05 H1 2 19:IL11 H1 1 22:IA15 H1 1 
2:IA92 H1 5:CA09 H1pdm  8:IA04 H1 11:MN15 H1 14:IA30 cH1 17:OK08 H1 1 FS 20:OK14 H1 1 23:SD15 H1 1 
3:MN11 H1 6:IA12 H1 -2 9:MN02 H1 12:IL08 H1 15:NC05 H1 2 FS 18:ON04 H1 1 21:MN15a H1 1 24:MN15b H1 1 
Strain 
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strains in the comparisons. In Figure 3, each axis corresponds to 1 
virus HA sequence. The HA sequences are sorted clockwise by nu-
cleotide identity, relative to the FS vaccine strain (IA00 H1γ FS virus). 
These radar plot figures highlight differences between EpiCC scores 
(distance) and sequence identity (see IA12 H1γ- 2 and IA15 H1γ, for 
example). The highest EpiCC score for each plot is given by E(v,v)A, that 
is, vaccine compared to itself.
We also found that the relationship between identity and EpiCC 
scores was nonlinear second- order polynomial (Figure 4; R2=0.94- 0.98). 
Unlike identity, EpiCC scores reflect important differences in amino 
acids contained in predicted T- cell epitopes and do not attribute value 
to amino acids that are not found in epitopes. For example, there are 
35 amino acids that differ between the vaccine strain IA00 H1γ FS 
and the field virus CA09 H1pdm, but only 16 of these amino acids 
were involved in putative SLA binders and had an effect on the class 
II EpiCC score. Furthermore, only 4 of the residues were contained in 
9- mers that were predicted to bind to 3 or more class II SLA alleles. 
Thus, EpiCC score may more accurately reflect relevant immunologi-
cal identity between sequences. EpiCC scores for sequences that had 
approximately 40% identity were no different from EpiCC scores for a 
random amino acid sequence of similar length. Similar results were ob-
served for correlation with HA nucleotide sequence identity (Fig. S4).
3.4 | Relationship between EpiCC scores and 
vaccine efficacy
Having calculated the EpiCC scores for 23 IAV strains, we then used 
the results of previously reported vaccine efficacy studies for the FS 
H1N1 γ- cluster vaccine strain (IA00 H1γ FS) against heterologous 
viruses representing α, β, γ, or H1pdm clusters (Table 2) to define a 
threshold of HA T- cell epitope relatedness between vaccine and chal-
lenge H1N1 strains that could be associated with protection. This in-
formation was not provided prior to conducting the EpiCC scoring. The 
primary measure for assessing vaccine efficacy in these studies was 
reduction in lung lesions; the reductions in viral nasal shedding and/or 
virus titers in the lung or lavage fluid at necropsy were considered to 
be secondary outcomes. The inactivated vaccine was considered pro-
tective in our analysis if there was a reduction in macroscopic pneu-
monia as well as reduction in virus titers in nasal swabs and/or in lung 
specimens collected at necropsy. If the vaccine significantly reduced 
virus titers, but not lung lesions, it was considered partially protective.
For the 6 vaccine efficacy studies considered in this analysis, FS 
conferred protection against challenge with 5 different H1N1 cluster 
viruses (Table 2). In 5 of the 6 studies, protection was conferred de-
spite low levels of HI cross- reactive antibodies (HI GMT to challenge 
virus	≤20)	measured	at	the	day	of	the	challenge.	For	these	studies,	the	
threshold associated with protective efficacy was defined as the low-
est	total	EpiCC	score	(EpiCC	score	of	−0.001;	MN02	H1β) comparing 
these 5 challenge strains with the vaccine strain (IA00 H1γ FS). This 
threshold defines the white area in Figure 5. For strains with EpiCC 
scores above the threshold, the scores of shared epitopes represented 
at least 67% (0.076) of the vaccine’s baseline HA EpiCC score (0.114; 
Table 1), which may suggest that a field virus or a vaccine strain (or 
both) may have many unique epitopes, but as long as there is a suffi-
cient level of shared epitopes relative to the baseline, an inactivated 
vaccine will be protective.
F I G U R E  3 EpiCC score comparisons between hemagglutinin (HA) sequences of FluSure vaccine (FS) viruses and field viruses. Each axis 
corresponds to the HA sequence of 1 virus. EpiCC score = Scores of shared epitopes - Scores of strain- and vaccine- unique epitopes. HA 
sequences in the same cluster had the highest EpiCC scores. For each vaccine virus, class I and II EpiCC scores were significantly different from 
each other (P < .05). Note that for comparisons where the score for unique epitopes was greater than the score for shared epitopes, EpiCC 
scores were below zero
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Additionally, the IA00 H1γ vaccine induced partial protection 
against challenge with IL08 H1α.	This	EpiCC	score	(−0.038)	was	con-
sidered a threshold associated with partial protection. This threshold 
separates the light gray from the dark gray area in Figure 5. IL08 H1α’s 
shared epitopes score was 58.4% (0.066) of the vaccine’s baseline 
EpiCC score. EpiCC scores for the H1δ cluster viruses, IA30 cH1 and 
SD15 H1α strains were below the partial protection threshold in the 
dark gray area.
Based on the association between total EpiCC scores of HA and 
vaccine efficacy, we speculate that immunization with the IA00 H1γ 
FS vaccine strain could confer protection against challenge with vi-
ruses	with	 scores	 above	−0.001	 (white	 area	 in	 Figure	5)	 and	partial	
protection for challenge- vaccine EpiCC scores between - 0.001 and 
−0.038	(light	gray	area	in	Figure	5),	assuming	minimal	variation	in	inter-
nal antigens. Although specific vaccine efficacy data were not available 
for heterologous challenges performed with viruses for which EpiCC 
scores fall in the dark gray area of Figure 5, we would hypothesize that 
the vaccine might not be protective against these strains. Important 
differences between strain identity and EpiCC scores can be identi-
fied; for example, the nucleotide sequence of IA12 H1γ- 2 virus HA 
is highly identical to IA00 H1γ FS (93.36%); however, its total EpiCC 
score	(−0.023)	is	below	the	threshold	associated	with	protection,	but	
above the threshold for partial protection. The low total EpiCC score 
is driven by a low score for shared epitopes (0.069; 60.2%) and high 
score for unique epitopes (0.092; Table 1). Nevertheless, shared epi-
topes between IA00 H1γ FS and IA12 H1γ- 2 virus HA might still con-
tribute to a certain level of protection.
4  | DISCUSSION
EpiCC is a method for assessing the relationship between field and 
vaccine strains of pathogens using predicted T- cell epitope content 
as a metric for comparison; here it is applied to IAV and vaccination/
challenge studies performed in swine. As compared to standard meth-
ods for estimating vaccine efficacy, such as determining whether im-
munization induces cross- reactive antibodies to the HA proteins, or 
measuring genetic differences by sequence similarity, EpiCC charac-
terizes the differences based on portions of the virus that the immune 
system processes and presents to T cells that drive potentially protec-
tive responses.
In our first test of the EpiCC scoring system, we compared the 
T- cell epitope content of 20 HA sequences from different H1 clus-
ters present in the North American swine population to that of 3 HA 
F IGURE  4 Relationship between EpiCC scores and hemagglutinin (HA) amino acid identity. The second- order polynomial relationship 
between class I (top) and II (bottom) EpiCC scores and amino acid identity for each FS virus is shown. R2 values of regression models are 
shown. H2N3, H5N1, H5N2, H3N2, H4N6, and a random sequence were included in this analysis to represent the lower end of the identity 
range. Interestingly, there were instances where viruses had low EpiCC scores despite high identity (eg, class II epitope content of IA00 H1γ FS 
compared to SD15 H1α)
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sequences from H1 viruses contained in a commercial swine IAV in-
activated vaccine. To evaluate whether T- cell epitope relatedness 
between vaccine and non- homologous challenge strains was associ-
ated with protection, we compared EpiCC scores with experimental 
outcomes of efficacy studies of FS H1N1γ vaccine virus where protec-
tion was induced in the absence of high levels of cross-reactive HA anti-
bodies. The results of the analysis, performed without foreknowledge 
of efficacy outcomes, showed a threshold of T- cell epitope relatedness 
that explained protection.
We do not yet know whether the threshold score would apply 
to new strains or different vaccines. The thresholds described in this 
study were based on experimental data from only 6 vaccine efficacy 
studies against challenge with cH1N1- lineage viruses. Additional 
efficacy studies would help to refine and validate the thresholds 
for prediction of protection and partial protection as well as lack of 
protection, and permit the evaluation of permutations of the EpiCC 
calculation. In this version of the EpiCC calculation we prioritized epi-
tope content shared between sequences and penalized strain- and 
vaccine- unique epitopes; this is based on an assumption that response 
to shared epitopes is protective while response to unique epitopes is 
not, which may not be entirely true. Further studies will be required 
to extend these findings to other IAV strains, to determine whether 
EpiCC scores can be used to define thresholds of vaccine efficacy for 
other important swine pathogens, and whether EpiCC could be used 
to select influenza strains for human vaccines.
We note that the set of MHC alleles used for the prediction of 
epitopes influenced the scores of shared and unique epitopes, and 
therefore the EpiCC scores, between vaccine strains and field viruses. 
To illustrate this point, baseline EpiCC scores calculated using binding 
predictions to SLA alleles were shown to be different from those de-
termined using a set of supertype HLA alleles. EpiCC scores for SLA- I 
alleles were significantly lower than those for HLA- I alleles and SLA- 
II- based scores were higher than HLA- II EpiCC scores. For this study, 
SLA allele selection was based on frequencies determined using low- 
resolution haplotyping for a small number of pigs.22 The relevance of 
these differences using distinct sets of MHC alleles is unknown; how-
ever, the distribution of SLA alleles for the North American swine pop-
ulation has yet to be defined, and therefore, the EpiCC scores might be 
TABLE  2 FluSure XP® vaccination and H1N1 challenge studies
Heterologous 
challenge Measurement of protectiona
HI GMT to 
challenge 
(vaccine)b 
virus Outcomec Ref.
Total EpiCC 
score 
(×102)H1N1 Virus
Percentage of 
macroscopic 
pneumonia
Virus titers in nasal 
swabs Virus titers in lungs
MN02 H1β Reduced Reduced Not available 80 (381) Protection 7 5.38
IA92 H1α Significantly reduced Significantly reduced Not available ≤20	(320) Protection 9 1.61
CA09 H1pdm Significantly reduced Significantly reduced Significantly reduced ≤10	(53d) Protection 6 0.63
OH10 H1γ Significantly reduced Not available Significantly reduced ≤10	(109) Protection 10 1.64
MN11 H1γ Significantly reduced Significantly reduced Significantly reduced ≤20	(117) Protection 11 2.10
IL08 H1α Not significantly 
different
Significantly reduced Significantly reduced ≤20	(240) Partial protection 12 -­1.34
aSignificance of outcomes was as measured and reported in the original references.
bHI GMT to the challenge and homologous viruses are shown.
cThe vaccine was considered protective if it reduced macroscopic pneumonia and virus titers in nasal swabs and/or in lungs collected at necropsy. If the 
vaccine significantly reduced virus titers, but not lung lesions, it was considered partially protective.
dHI GMT to a heterologous γ- cluster virus (A/Swine/OH/51145/2007 H1N1).
F IGURE  5 Definition of threshold for prediction of vaccine 
efficacy prediction. Total EpiCC scores (sum of class I and II EpiCC 
scores; blue line) for the comparison of H1γ FS and each viral strain 
are shown. The FS γ- cluster vaccine strain was protective or partially 
protective against challenge with viruses annotated as (P) or (PP), 
respectively. The rest of the viruses were not tested as challenge 
strains. Protection and partial protection thresholds (black lines) 
defined 3 areas shown in white (protection; total EpiCC score above 
−0.001),	light	gray	(partial	protection),	and	dark	gray	(no	protection).	
Viruses used to set the thresholds are marked with an asterisk (*). We 
hypothesize that FS would confer at least partial protection against 
challenge with viruses that had EpiCC scores outside the darker gray 
region
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different using a more comprehensive set of alleles. Development of a 
high- throughput SLA typing system paired with a systematic study of 
SLA diversity would improve the utility of the EpiCC analysis for swine 
populations not only for IAV, but also for other economically important 
pathogens affecting the swine industry. EpiCC scores were developed 
for populations of swine (and humans). Some vaccines may be more or 
less protective for a given individual, depending on the EpiCC scores 
for that individual’s SLA (or HLA) alleles.
In this case study, we were unable to determine which compo-
nent of the score (shared class II epitopes or shared class I epitopes, 
for example), is more important for predicting protection. Published 
information describing T cell–dependent (CMI) responses elicited by 
swine IAV vaccines is scarce and some studies have reported that CMI 
responses to inactivated vaccines can be limited in pigs.36 However, 
other studies showed that inactivated vaccines can prime the 
CD4 + CD8 +  (double- positive) memory T- cell subset.9,37,38 Porcine 
CD4 + CD8 +  T cells are MHC class II- restricted memory cells that 
express perforin and mediate cytolytic activity against virus- infected 
cells.39,40 For the set of alleles used for epitope prediction in this anal-
ysis, we found higher scores for class II epitopes shared between vac-
cines and field virus HAs compared to those of class I. Should further 
studies determine that cross- reactive class II epitopes are more rele-
vant for protection with inactivated vaccines, a weighted EpiCC score 
that favors class II epitopes could be applied.
Based on these findings, EpiCC scores showing high levels of T- 
cell epitope relatedness support the hypothesis that T- cell responses 
are involved in protection against challenge that is observed in the ab-
sence of HI cross- reactivity in experimental efficacy studies of the FS 
γ- cluster vaccine virus. The IA00 H1γ FS vaccine virus is clearly genet-
ically and antigenically (by HI titer) distinct from the challenge viruses 
used in the 6 experimental challenge studies for which efficacy data 
were available. However, under the conditions of these experimental 
studies, vaccination with FS provided protection or partial protection 
against MN11 H1γ, IA92 H1α, OH10 H1γ, and CA09 H1pdm with 
HI titers lower than 1:40 (the cutoff generally considered predictive 
of protection by antibodies).6,9-11 We observe that MN11 H1γ, IA92 
H1α, and OH10 H1γ had the highest EpiCC scores among evaluated 
HA sequences when compared to IA00 H1γ FS; CA09 H1pdm had the 
sixth highest score. Among these H1N1 viruses, only IA92 H1α and 
CA09 H1pdm have different internal genes.3 IA92 H1α predates the 
emergence of TRIG, and CA09 H1pdm was classified as a swine- origin 
IAV because internal and HA gene segments were genetically similar 
to those in the triple- reassortant viruses circulating in North American 
swine.41 Some differences in strain- specific T- cell epitope content of 
internal proteins should be expected. Notwithstanding these potential 
differences in the internal genes, the IA00 H1γ FS vaccine was protec-
tive against challenge with both strains.6,9 This result may suggest that 
a certain level of shared T- cell epitopes could be associated with pro-
tection, despite the presence of unique epitopes. Antibodies to other 
surface antigens, such as NA, may have also played a role in protection.
The role of T- cell epitopes in the highly variable external IAV 
protein, HA in protection against influenza in pigs is not yet known; 
however, human studies showed that vaccination with a monovalent 
subunit CA09 H1pdm vaccine elicited robust HA- specific CD4 T- cell 
responses dominated by memory CD4 T cells specific for peptides 
shared between the seasonal and pandemic strain.42 Researchers 
also demonstrated that expansion of CD4 T cells specific for peptide 
epitopes within HA, but not NP, correlated with neutralizing antibody 
response.42 These results support the notion that a greater degree of 
CD4 T- cell cross- reactivity (and higher class II EpiCC scores) may be 
associated with improved antibody response.
T cell–mediated responses directed to the conserved internal 
proteins of influenza viruses may have contributed to protection, as 
epitopes are more highly cross- conserved than the epitopes found in 
HA.43,44 In pigs, 2 evolutionary lineages (H1pdm09 and TRIG) domi-
nate the selection of internal genes in the circulating influenza viruses, 
leading to a high degree of conservation in the internal genes.3,23,24 We 
have previously identified highly conserved SLA- restricted epitopes 
in the NA and M proteins that are found in different IAV subtypes.22 
Other groups have also reported conserved SLA class I- restricted epi-
topes in NA.45,46 This EpiCC analysis focuses on HA (while disregarding 
conserved internal and other external genes), as much of the antigenic 
variability between IAV strains circulating in swine (and differences in 
protection by vaccine strains) is localized to the HA surface antigen. 
Moreover, the predominant antibody response induced by inactivated 
vaccines is driven by antibodies to the HA protein. Therefore, these re-
sults are most relevant to inactivated vaccines, whole virus and HA sub-
unit vaccines, and vectored vaccines containing the HA protein. Future 
studies will compare the utility of including other surface antigens (such 
as NA and M2) in the EpiCC score to determine whether thresholds re-
vealed by HA- specific T- cell epitope relatedness can be further refined.
Genetic sequence comparison of HA is also used for predicting 
potential cross- protective efficacy of vaccines. The relationship be-
tween EpiCC scores and HA amino acid sequence identity was non-
linear. At approximately 40% identity, epitope- based relatedness was 
similar to the EpiCC score of a random amino acid sequence of the 
same length. And while changes in amino acids affecting T- cell epi-
topes can have a significant impact on the immunogenicity of an an-
tigen,47,48 their effect on whole antigen sequence similarity may be 
minimal. To illustrate this point, we found viruses that had low EpiCC 
scores despite having high sequence identity. For example, when 
IA00 H1γ FS is compared to IA12 H1γ- 2, the nucleotide identity is 
93.36% and the EpiCC score is above the threshold set for partial 
protection, but below the threshold for protection. Although H1γ- 2 
cluster viruses were infrequently detected in the US swine popula-
tion, characterization of H1γ- 2 viruses demonstrated divergent anti-
genic properties with viruses within the same clade and viruses from 
contemporary swine H1 clusters as well as commercial vaccines, sug-
gesting a potential risk of vaccine failure against some H1γ- 2 viruses.3 
On the contrary, EpiCC analysis suggests that the H1γ cluster vaccine 
virus may induce at least partial protection against IA12 H1γ- 2 virus.
In conclusion, we developed the EpiCC algorithm to assess the immu-
nological relatedness between vaccines and emerging pathogen antigens 
based on their predicted T- cell epitope content. Using EpiCC in a case 
study of swine influenza viruses, we found that vaccine protection con-
ferred by the FS IA00 H1 γ- cluster, in the absence of HI cross- reactive 
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antibodies, might be explained by predicted T- cell epitope content relat-
edness between challenge and vaccine viruses. Based on these results, we 
proposed EpiCC score thresholds for prediction of full and partial protec-
tion. EpiCC scores were dependent on a set of swine MHC alleles used for 
the predictions of epitopes; thus, future EpiCC scores for these sequences 
may differ from the scores reported here. As information about SLA prev-
alence in North American swine populations becomes available, the im-
pact of MHC allele selection on EpiCC scores will be assessed further.
This study provides preliminary evidence that EpiCC may comple-
ment current methods (HI cross- reactivity and phylogenetic analysis) for 
selecting the best- matched vaccine virus for immunization against emerg-
ing swine IAVs. Additional data from vaccine efficacy studies in swine and 
other species will be useful to validate and optimize these thresholds and 
extend the usefulness of EpiCC to other human and swine pathogens and 
available (or future) vaccines.
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